Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines

被引:74
作者
Brandon, EFA
Bosch, TM
Deenen, MJ
Levink, R
van der Wal, E
van Meerveld, JBM
Bijl, M
Beijnen, JH
Schellens, JHM
Meijerman, I
机构
[1] Univ Utrecht, Fac Pharmaceut Sci, Sect Drug Toxicol, Dept Biomed Anal, NL-3584 CA Utrecht, Netherlands
[2] Slotervaart Hosp, Netherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands
[3] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Med Oncol & Expt Therapy, Amsterdam, Netherlands
关键词
genetic polymorphisms; IGROV-1; HepG2; CaCo-2; LS180 cytochrome P450; phase II enzymes; drug transporters;
D O I
10.1016/j.taap.2005.05.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human cell lines are often used for in vitro biotransformation and transport studies of drugs. In vivo.. genetic polymorphisms have been identified in drug-metabolizing enzymes and ABC-drug transporters leading to altered enzyme activity, or a chance in the inducibility of these enzymes. These genetic polymorphisms could also influence the outcome Of Studies using human cell lines. Therefore, the aim of our study was to pharmacogenotype four cell lines frequently used in drug metabolism and transport studies, HepG2, IGROV-1, CaCo-2 and LS180, for genetic polymorphisms in biotransformation enzymes and drug transporters. The results indicate that, despite the presence of some genetic polymorphisms, no real effects influencing the activity of metabolizing enzymes or drug transporters in the investigated cell lines are expected. However, this characterization will be an aid in the interpretation of the results of biotransformation and transport studies using these in vitro cell models. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 79 条
[1]   Genetic polymorphism of CYP1A2 in ethiopians affecting induction and expression: Characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1 [J].
Aklillu, E ;
Carrillo, JA ;
Makonnen, E ;
Hellman, K ;
Pitarque, M ;
Bertilsson, L ;
Ingelman-Sundberg, M .
MOLECULAR PHARMACOLOGY, 2003, 64 (03) :659-669
[2]   Caco-2 monolayers in experimental and theoretical predictions of drug transport (Reprinted from Advanced Drug Delivery Reviews, vol 22, pg 67-84, 1996) [J].
Artursson, P ;
Palm, K ;
Luthman, K .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 46 (1-3) :27-43
[3]   CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes [J].
Bahadur, N ;
Leathart, JBS ;
Mutch, E ;
Steimel-Crespi, D ;
Dunn, SA ;
Gilissen, R ;
Van Houdt, J ;
Hendrickx, J ;
Mannens, G ;
Bohets, H ;
Williams, FM ;
Armstrong, M ;
Crespi, CL ;
Daly, AK .
BIOCHEMICAL PHARMACOLOGY, 2002, 64 (11) :1579-1589
[4]   Peroxisome proliferator-activated receptor α induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme [J].
Barbier, O ;
Duran-Sandoval, D ;
Pineda-Torra, I ;
Kosykh, V ;
Fruchart, JC ;
Staels, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (35) :32852-32860
[5]   DETOXICATION OF BASE PROPENALS AND OTHER ALPHA,BETA-UNSATURATED ALDEHYDE PRODUCTS OF RADICAL REACTIONS AND LIPID-PEROXIDATION BY HUMAN GLUTATHIONE TRANSFERASES [J].
BERHANE, K ;
WIDERSTEN, M ;
ENGSTROM, A ;
KOZARICH, JW ;
MANNERVIK, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (04) :1480-1484
[6]   Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance [J].
Bhasker, CR ;
McKinnon, W ;
Stone, A ;
Lo, ACT ;
Kubota, T ;
Ishizaki, T ;
Miners, JO .
PHARMACOGENETICS, 2000, 10 (08) :679-685
[7]  
BOLT HM, 2004, ARCH TOXICOL, P19
[8]   Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population [J].
Bosch, TM ;
Kjellberg, LM ;
Bouwers, A ;
Koeleman, BPC ;
Schellens, JHM ;
Beijnen, JH ;
Smits, PHM ;
Meijerman, I .
AMERICAN JOURNAL OF PHARMACOGENOMICS, 2005, 5 (02) :123-131
[9]   THE GENETIC-BASIS OF THE REDUCED EXPRESSION OF BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE-1 IN GILBERTS-SYNDROME [J].
BOSMA, PJ ;
CHOWDHURY, JR ;
BAKKER, C ;
GANTLA, S ;
DEBOER, A ;
OOSTRA, BA ;
LINDHOUT, D ;
TYTGAT, GNJ ;
JANSEN, PLM ;
ELFERINK, RPJO ;
CHOWDHURY, NR .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (18) :1171-1175
[10]   An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons [J].
Brandon, EFA ;
Raap, CD ;
Meijerman, I ;
Beijnen, JH ;
Schellens, JHM .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2003, 189 (03) :233-246